



July 27, 2022

Better Care Plastic Technology Co., Ltd.  
% Kathy Liu  
Project Manager  
Hongray USA Medical Products Inc.  
3973 Schaefer Avenue, Chino, CA 91710, USA  
Chino, California 91710

Re: K221269

Trade/Device Name: Powder Free Nitrile Examination Gloves (Blue), Tested for Use with  
Chemotherapy Drugs and Fentanyl Citrate

Regulation Number: 21 CFR 880.6250

Regulation Name: Non-Powdered Patient Examination Glove

Regulatory Class: Class I, reserved

Product Code: LZA, LZC, QDO

Dated: April 18, 2022

Received: May 2, 2022

Dear Kathy Liu:

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database located at <https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm> identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803) for devices or postmarketing safety reporting (21 CFR 4, Subpart B) for combination products (see <https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reporting-combination-products>); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to <https://www.fda.gov/medical-devices/medical-device-safety/medical-device-reporting-mdr-how-report-medical-device-problems>.

For comprehensive regulatory information about medical devices and radiation-emitting products, including information about labeling regulations, please see Device Advice (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance>) and CDRH Learn (<https://www.fda.gov/training-and-continuing-education/cdrh-learn>). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (<https://www.fda.gov/medical-devices/device-advice-comprehensive-regulatory-assistance/contact-us-division-industry-and-consumer-education-dice>) for more information or contact DICE by email ([DICE@fda.hhs.gov](mailto:DICE@fda.hhs.gov)) or phone (1-800-638-2041 or 301-796-7100).

Sincerely,

Bifeng Qian, M.D., Ph.D.  
Assistant Director  
DHT4B: Division of Infection Control  
and Plastic Surgery Devices  
OHT4: Office of Surgical  
and Infection Control Devices  
Office of Product Evaluation and Quality  
Center for Devices and Radiological Health

Enclosure

## Indications for Use

510(k) Number (if known)  
K221269

Device Name

Powder Free Nitrile Examination Gloves (Blue), Tested for Use with Chemotherapy Drugs and Fentanyl Citrate

Indications for Use (Describe)

The glove is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner.

Gloves have been tested for use with chemotherapy drugs and Fentanyl Citrate using ASTM D6978-05(2019)

Chemotherapy Drug	Minimum Breakthrough Detection Time (BDT) in Minutes
Bleomycin Sulfate 15mg/ml (15000 ppm)	>240
Busulfan 6mg/ml (6,000 ppm)	>240
Carboplatin 10mg/ml (10,000 ppm)	>240
Carmustine (BCNU) 3.3 mg/ml (3,300 ppm)	11.1
Chloroquine 50mg/ml (50,000ppm)	>240
Cisplatin 1mg/ml (1,000 ppm)	>240
Cyclophosphamide 20mg/ml (20,000 ppm)	>240
Cyclosporin 100 mg/ml (100,000 ppm)	>240
Cytarabine HCL, 100 mg/ml (100,000 ppm)	>240
Dacarbazine 10 mg/ml (10,000 ppm)	>240
Daunorubicin HCL, 5 mg/ml (5,000 ppm)	>240
Docetaxel, 10 mg/ml (10,000 ppm)	>240
Doxorubicin HCL, 2 mg/ml (2,000 ppm)	>240
Epirubicin HCL, 2 mg/ml (2,000 ppm)	>240
Etoposide, 20 mg/ml (20,000 ppm)	>240
Fludarabine, 25 mg/ml (25,000 ppm)	>240
Fluorouracil, 50mg/ml (50,000ppm)	>240
Gemcitabine, 38mg/ml (38,000ppm)	>240
Idarubicin HCL, 1mg/ml (1,000ppm)	>240
Ifosfamide, 50mg/ml (50,000ppm)	>240
Irinotecan, 20mg/ml (20,000ppm)	>240
Mechlorethamine HCl, 1mg/ml (1,000ppm)	>240
Melphalan, 5mg/ml (5,000ppm)	>240
Methotrexate, 25mg/ml (25,000ppm)	>240
Mitomycin C, 0.5mg/ml (500ppm)	>240
Mitoxantrone HCL, 2mg/ml (2,000ppm)	>240
Oxaliplatin, 5mg/ml (5,000ppm)	>240
Paclitaxel, 6mg/ml (6,000ppm)	>240
Paraplatin, 10mg/ml (10,000ppm)	>240
Retrovir, 10mg/ml (10,000ppm)	>240
Rituximab, 10mg/ml (10,000ppm)	>240
Thio Tapa, 10mg/ml (10,000ppm)	21.6
Topotecan, 1mg/ml (1,000ppm)	>240
Trisenox, 1mg/ml (1,000ppm)	>240
Velcade, 1mg/ml (1,000ppm)	>240
Vincristine Sulfate, 1mg/ml (1,000ppm)	>240
Fentanyl Citrate Injection (100 mcg/2ml)	>240

Please note that the following drugs have extremely low permeation times:

---

Carmustine: 11.1 minutes, Thio Tapa: 21.6 minutes

\*Warning: Do not use with Carmustine and Thio Tapa.

---

Type of Use (Select one or both, as applicable)

Prescription Use (Part 21 CFR 801 Subpart D)

Over-The-Counter Use (21 CFR 801 Subpart C)

---

---

**CONTINUE ON A SEPARATE PAGE IF NEEDED.**

---

This section applies only to requirements of the Paperwork Reduction Act of 1995.

**\*DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.\***

The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:

Department of Health and Human Services  
Food and Drug Administration  
Office of Chief Information Officer  
Paperwork Reduction Act (PRA) Staff  
[PRAStaff@fda.hhs.gov](mailto:PRAStaff@fda.hhs.gov)

*"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."*

# Better Care Plastic Technology Co., Ltd

Fuqian Xi Road, West district of Shenze, Industrial Base,  
Shenze County, Hebei, 050000, China

## 510K Summary

The assigned 510(K) numbers: K221269

Date Prepared: July 22, 2022

### **1. Owner's Identification:**

Better Care Plastic Technology Co., Ltd.

Fuqian Xi Road, West district of Shenze, Industrial Base, Shenze County, Hebei, 050000, China

Tel:86-311-66179668

Contact: Ms. Kathy Liu, Project Manager

Address: 3973 Schaefer Avenue, Chino, CA 91710, USA

Tel:909-590-1611

Email: [kathyliu@honggrayusa.com](mailto:kathyliu@honggrayusa.com) or [fdareg@honggray.com.cn](mailto:fdareg@honggray.com.cn)

### **2. Name of the Device:**

Trade / Product Name: Powder Free Nitrile Examination Gloves (Blue), Tested for Use with  
Chemotherapy Drugs and Fentanyl Citrate

Common Name: Exam Gloves

Classification Name: Patient Examination Glove Specialty

Classification Regulation: 21 CFR 880.6250

Product Code: LZA, LZC, QDO

Classification Panel: General Hospital

Device Class: Class I

### **3. Predicate Device Information:**

Comfort Rubber Gloves Industries Sdn. Bhd.

Blue Colored, Power Free Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs and  
Fentanyl Citrate (K192954)

### **4. Device Description:**

Powder Free Nitrile Examination Gloves (Blue), Tested for Use with Chemotherapy Drugs and Fentanyl  
Citrate Are Class I Patient Examination Gloves and Specialty Chemotherapy Gloves. They are  
ambidextrous and come in different sizes – Extra Small, Small, Medium, Large, Extra Large and XXL.  
Gloves meet the specification of ASTM D6319-19 and have been tested for resistance to permeation by  
chemotherapy drugs and Fentanyl Citrate as per ASTM D6978-05(2019). The gloves are single use,  
disposable, and provided non-sterile.

### **5. Indications for Use:**

Powder Free Nitrile Examination Gloves (Blue), Tested for Use with Chemotherapy Drugs and Fentanyl  
Citrate is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent  
contamination between patient and examiner.

Gloves have been tested for use with chemotherapy drugs and Fentanyl Citrate using ASTM D6978-  
05(2019)

## Better Care Plastic Technology Co., Ltd

Fuqian Xi Road, West district of Shenze, Industrial Base,  
Shenze County, Hebei, 050000, China

### 510K Summary

The following chemicals have been tested with these gloves:

Chemotherapy Drug	Minimum Breakthrough Detection Time (BDT) in Minutes
Bleomycin Sulfate 15mg/ml (15000 ppm)	>240
Busulfan 6mg/ml (6,000 ppm)	>240
Carboplatin 10mg/ml (10,000 ppm)	>240
Carmustine (BCNU)3.3 mg/ml (3,300 ppm)	11.1
Chloroquine 50mg/ml (50,000ppm)	>240
Cisplatin 1mg/ml (1,000 ppm)	>240
Cyclophosphamide 20mg/ml (20,000 ppm)	>240
Cyclosporin 100 mg/ml (100,000 ppm)	>240
Cytarabine HCL, 100 mg/ml (100,000 ppm)	>240
Dacarbazine 10 mg/ml (10,000 ppm)	>240
Daunorubicin HCL, 5 mg/ml (5,000 ppm)	>240
Docetaxel, 10 mg/ml (10,000 ppm)	>240
Doxorubicin HCL, 2 mg/ml (2,000 ppm)	>240
Epirubicin HCL, 2 mg/ml (2,000 ppm)	>240
Etoposide, 20 mg/ml (20,000 ppm)	>240
Fludarabine, 25 mg/ml (25,000 ppm)	>240
Fluorouracil, 50mg/ml (50,000ppm)	>240
Gemcitabine, 38mg/ml (38,000ppm)	>240
Idarubicin HCL, 1mg/ml (1,000ppm)	>240
Ifosfamide, 50mg/ml (50,000ppm)	>240
Irinotecan, 20mg/ml (20,000ppm)	>240
Mechlorethamine HCl, 1mg/ml (1,000ppm)	>240
Melphalan, 5mg/ml (5,000ppm)	>240
Methotrexate, 25mg/ml (25,000ppm)	>240
Mitomycin C, 0.5mg/ml (500ppm)	>240
Mitoxantrone HCL, 2mg/ml (2,000ppm)	>240
Oxaliplatin, 5mg/ml (5,000ppm)	>240
Paclitaxel, 6mg/ml (6,000ppm)	>240
Paraplatin, 10mg/ml (10,000ppm)	>240
Retrovir, 10mg/ml (10,000ppm)	>240
Rituximab, 10mg/ml (10,000ppm)	>240
Thio Tapa, 10mg/ml (10,000ppm)	21.6
Topotecan, 1mg/ml (1,000ppm)	>240
Trisenox, 1mg/ml (1,000ppm)	>240
Velcade, 1mg/ml (1,000ppm)	>240

## Better Care Plastic Technology Co., Ltd

Fuqian Xi Road, West district of Shenze, Industrial Base,  
Shenze County, Hebei, 050000, China

### 510K Summary

Vincristine Sulfate, 1mg/ml (1,000ppm)	>240
Fentanyl Citrate Injection (100 mcg/2ml)	>240

\*Please note that the following drugs have extremely low permeation times:

Carmustine: 11.1 minutes, Thio Tepa: 21.6 minutes

Warning: Do not use with Carmustine and Thio Tepa.

### 6. Comparison of Subject Device and Predicate Device:

General Comparison Table:

	Proposed Device K221269	Predicate Device K192954	Comparison
Trade Name	Powder Free Nitrile Examination Gloves (Blue), Tested for Use with Chemotherapy Drugs and Fentanyl Citrate	Blue Colored, Powder Free Nitrile Examination Gloves Tested for Use with Chemotherapy Drugs and Fentanyl Citrate	Similar
Product Code	LZA, LZC, QDO	LZA, LZC, QDO	Same
Regulation Number	21 CFR 880.6250	21 CFR 880.6250	Same
Class	I	I	Same
Indications for Use	Powder Free Nitrile Examination Gloves (Blue), Tested for Use with Chemotherapy Drugs and Fentanyl Citrate is a disposable device intended for medical purposes that is worn on the examiner's hand to prevent contamination between patient and examiner. Gloves have been tested for use with chemotherapy drugs and Fentanyl Citrate using ASTM D6978	Blue Colored, Powder Free Nitrile Examination Gloves, Non-sterile, and Tested for Use with Chemotherapy Drugs and Fentanyl Citrate is a patient medical exam glove which is a disposable device intended for medical purpose that is worn on the examiner's hand or finger to prevent contamination between examiner and patient. Glove was tested for use with Chemotherapy Drugs and Fentanyl Citrate as per ASTM D6978	Similar
Material	Nitrile	Nitrile	Same
Powder or Powder Free	Powder Free	Powder Free	Same
Color	Blue	Blue	Same
Single use	Single use	Single use	Same
Chemotherapy Drugs and Fentanyl Citrate Claim	See below comparison table	See below comparison table	See below comparison table

## Better Care Plastic Technology Co., Ltd

Fuqian Xi Road, West district of Shenze, Industrial Base,  
Shenze County, Hebei, 050000, China

### 510K Summary

Technological Characteristic Comparison Table:

Technological Characteristics	Proposed Device K221269	Predicate Device K192954	Comparison
Length	Minimum 230mm	Minimum 240mm	Similar
Palm Width (size) (mm)			
XS	70±10	70±10	Same
S	80±10	80±10	Same
M	95±10	95±10	Same
L	110±10	110±10	Same
XL	120±10	120±10	Same
XXL	130±10	N/A	Different
Thickness(mm)			
Finger	Minimum 0.05	Minimum 0.05	Same
Palm	Minimum 0.05	Minimum 0.05	Same
Tensile Strength, Before Aging	14MPa, min	14MPa, min	Same
Ultimate Elongation, Before Aging	500%, min	500%, min	Same
Tensile Strength, After Accelerated Aging	14MPa, min	14MPa, min	Same
Ultimate Elongation, After Accelerated Aging	400%, min	400%, min	Same
Watertight (1000ml)	21 CFR 800.20 ASTM D5151 AQL 2.5	21 CFR 800.20 ASTM D5151 AQL 2.5	Same
Powder-Content	≤ 2 mg per glove	≤ 2 mg per glove	Same
10993-10:2010 Skin Irritation Study	Under the conditions of the study, not an irritant	Under the conditions of the study, the subject device is non-irritating	Same
10993-10:2010 Maximization Sensitization Study	Under the conditions of the study, not a sensitizer	Under the conditions of the study, the subject device is non sensitization	Same
10993-5:2009 Cytotoxicity Test	Under the conditions of this study, the test article extract showed potential toxicity to L929 cells. Cytotoxicity concern was addressed by acute systematic toxicity testing.	Exhibits severe cytotoxicity reactivity at 100%, and 66% extract concentrations and no cytotoxicity reactivity at 44%, 30%, 20% and 15% extract concentrations under the condition of this test. Cytotoxicity concern was	Same



## Better Care Plastic Technology Co., Ltd

Fuqian Xi Road, West district of Shenze, Industrial Base,  
Shenze County, Hebei, 050000, China

### 510K Summary

		addressed by acute systematic toxicity testing.	
ISO 10993-11:2017 Acute Systemic toxicity study	Under the conditions of this study, there was no evidence of systemic toxicity.	Under the conditions of the study, the subject showed no adverse biological reaction.	Same

#### Chemotherapy Permeation and Fentanyl Citrate Comparison Claim:

Tested Chemotherapy Drug and Concentration	Minimum BDT (Minutes)		Comparison
	Proposed Device K221269	Predicate Device K192954	
Bleomycin Sulfate 15mg/ml (15000 ppm)	>240	N/A	Different
Busulfan 6mg/ml (6,000 ppm)	>240	N/A	Different
Carboplatin 10mg/ml (10,000 ppm)	>240	N/A	Different
Carmustine (BCNU)3.3 mg/ml (3,300 ppm)	11.1	18.2	Similar
Chloroquine 50mg/ml (50,000ppm)	>240	N/A	Different
Cisplatin 1mg/ml (1,000 ppm)	>240	>240	Same
Cyclophosphamide 20mg/ml (20,000 ppm)	>240	>240	Same
Cyclosporin 100 mg/ml (100,000 ppm)	>240	N/A	Different
Cytarabine HCL, 100 mg/ml (100,000 ppm)	>240	N/A	Different
Dacarbazine 10 mg/ml (10,000 ppm)	>240	>240	Same
Daunorubicin HCL, 5 mg/ml (5,000 ppm)	>240	N/A	Different
Docetaxel , 10 mg/ml (10,000 ppm)	>240	N/A	Different
Doxorubicin HCL, 2 mg/ml (2,000 ppm)	>240	>240	Same
Epirubicin HCL, 2 mg/ml (2,000 ppm)	>240	N/A	Different
Etoposide, 20 mg/ml (20,000 ppm)	>240	>240	Same
Fludarabine, 25 mg/ml (25,000 ppm)	>240	N/A	Different
Fluorouracil, 50mg/ml (50,000ppm)	>240	>240	Same
Gemcitabine, 38mg/ml (38,000ppm)	>240	N/A	Different
Idarubicin HCL, 1mg/ml (1,000ppm)	>240	N/A	Different
Ifosfamide, 50mg/ml (50,000ppm)	>240	N/A	Different
Irinotecan, 20mg/ml (20,000ppm)	>240	N/A	Different
Mechlorethamine HCl, 1mg/ml (1,000ppm)	>240	N/A	Different
Melphalan, 5mg/ml (5,000ppm)	>240	N/A	Different
Methotrexate, 25mg/ml (25,000ppm)	>240	N/A	Different
Mitomycin C, 0.5mg/ml (500ppm)	>240	N/A	Different
Mitoxantrone HCL, 2mg/ml (2,000ppm)	>240	N/A	Different
Oxaliplatin, 5mg/ml (5,000ppm)	>240	N/A	Different
Paclitaxel, 6mg/ml (6,000ppm)	>240	>240	Same
Paraplatin, 10mg/ml (10,000ppm)	>240	N/A	Different
Retrovir, 10mg/ml (10,000ppm)	>240	N/A	Different

## Better Care Plastic Technology Co., Ltd

Fuqian Xi Road, West district of Shenze, Industrial Base,  
Shenze County, Hebei, 050000, China

### 510K Summary

Rituximab, 10mg/ml (10,000ppm)	>240	N/A	Different
Thio Tapa, 10mg/ml (10,000ppm)	21.6	57.3	Similar
Topotecan, 1mg/ml (1,000ppm)	>240	N/A	Different
Trisenox, 1mg/ml (1,000ppm)	>240	N/A	Different
Velcade, 1mg/ml (1,000ppm)	>240	N/A	Different
Vincristine Sulfate, 1mg/ml (1,000ppm)	>240	N/A	Different
Fentanyl Citrate Injection (100 mcg/2ml)	>240	>240	Same

#### 7. Summary of Non-Clinical Performance Data

Non-clinical tests were conducted to verify that the proposed device met all design specifications. The test results demonstrated that the proposed device met the performance criteria with the following standards:

Methodology	Test Performed	Acceptance Criteria	Results
ASTM D6319- 19	Physical Dimensions Length	Minimum 230mm for all sizes	Pass
ASTM D6319- 19	Physical Dimensions Palm Width	XS: 70±10mm S: 80±10mm M: 95±10mm L:110±10mm XL: 120±10mm XXL: 130±10mm	Pass
ASTM D6319- 19	Physical Dimensions Thickness	Finger: 0.05mm (min) Palm: 0.05mm (min)	Pass
ASTM D6319- 19 ASTM D412-16(2021)	Physical Properties	Tensile Strength (Min14 MPa) and Elongation (Before Aging 500% and after aging 400%) Min	Pass
ASTM D6319- 19 ASTM D5151-19	Water leak test	AQL 2.5 (ISO 2859-1)	Pass
ASTM D6319- 19 ASTM D6124-06 (2017)	Powder Residue	Max 2mg/glove	Pass
ASTM D6978-05 (2019)	Permeation by Chemotherapy Drugs	Refer the above table 1	Pass
ISO 10993-10:2010	Irritation and Skin Sensitization	Skin sensitization and Skin irritation	Is non-sensitization and Non-irritation
ISO 10993-5:2009	Cytotoxicity	Cytotoxicity reactivity	showed potential toxicity to L929 cells.
ISO 10993-11:2017	Acute systemic toxicity study	Subject showed no adverse biological reaction	no evidence of systemic toxicity.

- ASTM D6319-19, Standard Specification for Nitrile Examination Gloves for Medical Application.

## **Better Care Plastic Technology Co., Ltd**

Fuqian Xi Road, West district of Shenze, Industrial Base,  
Shenze County, Hebei, 050000, China

### **510K Summary**

- ASTM D5151-19, Standard Test Method for Detection of Holes in Medical Gloves.
- ASTM D6124-06 (Reapproved 2017), Standard Test Method for Residual Powder on Medical Gloves
- ASTM D412-16 (2021) Standard Test Methods for Vulcanized Rubber and Thermoplastic Elastomers—Tension
- ASTM D6978-05 (Reapproved 2019), Assessment of Reissuance of Medical Gloves to Permeation by Chemotherapy Drugs.
- ISO 10993-10:2010 Biological Evaluation of Medical Devices - Part 10: Tests For Irritation And Skin Sensitization.
- ISO 10993-5:2009 Biological Evaluation of Medical Devices - Part 5: Tests For In Vitro Cytotoxicity
- ISO 10993-11:2017 Biological evaluation of medical devices — Part 11: Tests for systemic toxicity

#### **8. Clinical Performance Data**

N/A

#### **9. Conclusion:**

The conclusions drawn from the nonclinical tests demonstrate that the proposed device is as safe, as effective, and performs as well as or better than the legally marketed predicated device.